NexGel Files 10-K/A Amendment for FY 2023

TL;DR

NexGel filed an amendment to its 2023 annual report. Check for updates.

AI Summary

NexGel, Inc. filed an amendment (10-K/A) on June 13, 2024, for its fiscal year ending December 31, 2023. The company, formerly known as AquaMed Technologies, Inc. until July 23, 2009, is based in Langhorne, PA, and operates in the Surgical & Medical Instruments & Apparatus industry. This amendment likely provides updated or corrected information to their annual report.

Why It Matters

This filing provides updated information for investors and analysts regarding NexGel's financial performance and business operations for the fiscal year 2023, which could influence investment decisions.

Risk Assessment

Risk Level: low — This is an amendment to a previously filed annual report, indicating a correction or update rather than a new, significant event.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by the annual report.)
• 20240613 — Filing Date (The date the amendment was submitted to the SEC.)

Key Players & Entities

• NEXGEL, INC. (company) — Filer
• AquaMed Technologies, Inc. (company) — Former Company Name
• 2023-12-31 (date) — Fiscal Year End
• 20240613 (date) — Filing Date
• 001-41173 (other) — SEC File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 NXGL The Nasdaq Capital Market LLC

Filing Documents

• form10-ka.htm (10-K/A) — 74KB
• ex31-3.htm (EX-31.3) — 12KB
• ex31-4.htm (EX-31.4) — 12KB
• 0001493152-24-023728.txt ( ) — 371KB
• nxgl-20231231.xsd (EX-101.SCH) — 4KB
• nxgl-20231231_def.xml (EX-101.DEF) — 28KB
• nxgl-20231231_lab.xml (EX-101.LAB) — 38KB
• nxgl-20231231_pre.xml (EX-101.PRE) — 26KB
• form10-ka_htm.xml (XML) — 9KB

Controls and Procedures

Controls and Procedures As of December 31, 2023, we conducted an evaluation of the effectiveness of our "disclosure controls and procedures" ("Disclosure Controls"), as defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Disclosure Controls evaluation was done under the supervision and with the participation of management, including our chief executive officer and chief financial officer. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon this evaluation, our chief executive officer and chief financial officer have concluded that our Disclosure Controls and Procedures were effective as of December 31, 2023 at a reasonable level of assurance. Management's Annual Report on Internal Control over Financial Reporting and Attestation Report of the Registered Accounting Firm Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. Based on that assessment, management has concluded that its internal control over financial reporting was effective as of December 31, 2023 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with accounting

financial statements are filed with this Amendment. These items were included as part of the Original Report

financial statements are filed with this Amendment. These items were included as part of the Original Report. (2) Financial None. (3) Exhibits The exhibits listed in the Original Reports are required by Item 601 of Regulation S-K. A list of the exhibits filed with this Amendment are provided below Exhibit Number Description 31.3 * Certificate of Chief Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.4 * Certificate of Chief Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 104 Cover Page Interactive Data File (formatted as Inline XBRL) *Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Amendment to be signed on its behalf by the undersigned, thereunto duly authorized. NEXGEL, INC. Date: June 13, 2024 By: /s/ Adam Levy Adam Levy Chief Executive Officer, Director (Principal Executive Officer) Date: June 13, 2024 By: /s/ Adam E. Drapczuk Adam E. Drapczuk Chief Financial Officer

View Full Filing

View this 10-K/A filing on SEC EDGAR